New drug cocktail aims to fight advanced cervical cancer

NCT ID NCT04982237

Ongoing Disease control Sponsor: Akeso Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This Phase 3 trial is testing whether adding the immunotherapy AK104 to standard chemotherapy (with or without bevacizumab) helps people with advanced cervical cancer that cannot be cured by surgery or radiation. About 445 participants will receive either the drug combo or a placebo. The main goals are to see if the treatment slows cancer growth and improves survival.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: AK104 (a type of immunotherapy) plus chemotherapy (paclitaxel, carboplatin, or cisplatin) with or without bevacizumab
What this could lead to: If successful, this could offer a new first-line treatment option that helps people with advanced cervical cancer live longer and delay disease progression.
What could go wrong: This is an early-stage Phase 3 trial, so results are not yet confirmed. The treatment may not work better than standard care, and side effects from the combination therapy could be significant.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CERVICAL CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cervical cancer Uterine Cervical Neoplasms

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CERVICAL CANCER

Contacts and locations

Locations

Anhui Provincial Hospital

Hefei, China
Fudan University Shanghai Cancer Center

Shanghai, 200032, China
The Second Affiliated Hospital,Anhui Medical University

Hefei, China
Women's Hospital School Of Medicine Zhejiang University

Hangzhou, China
Zhejiang Cancer Hospital

Hangzhou, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.